PEG-uricase in the management of treatment-resistant gout and hyperuricemia
about
Pegloticase for chronic goutBiomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxicationLesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinolSite-Specific PEGylation of Therapeutic ProteinsThe emerging role of biotechnological drugs in the treatment of goutPolymer-drug conjugates: origins, progress to date and future directionsFunctional and Structural Characterization of Purine Nucleoside Phosphorylase from Kluyveromyces lactis and Its Potential Applications in Reducing Purine Content in FoodImpact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricaseEconomic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle)Gout: an Asia-Pacific update.Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivoA broader view: microbial enzymes and their relevance in industries, medicine, and beyond.Site-specific fatty acid-conjugation to prolong protein half-life in vivoPotential applications and human biosafety of nanomaterials used in nanomedicineTherapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftDesigning and engineering of a site-specific incorporation of a keto group in uricase.Macromolecular therapeuticsAn old disease with new insights: Update on diagnosis and treatment of gout.Comparison of activity indexes for recognizing enzyme mutants of higher activity with uricase as modelNew and improved strategies for the treatment of goutDevelopment of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APSUricases as therapeutic agents to treat refractory gout: Current states and future directions.Latest evidence on gout management: what the clinician needs to knowSite-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coliLong-term safety of pegloticase in chronic gout refractory to conventional treatment.Gout. Novel therapies for treatment of gout and hyperuricemia.Gout--what are the treatment options?Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trialsProduct development issues for PEGylated proteins.New advances in the treatment of gout: review of pegloticasePegloticase: in treatment-refractory chronic gout.Recent advances in management of gout.Pegloticase: a novel agent for treatment-refractory gout.Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives.Evaluation and treatment of gout as a chronic disease.Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.PEGylation and its impact on the design of new protein-based medicines.Enzymatic dissolution of calcium and struvite crystals: in vitro evaluation of biochemical requirements.Investigational drugs for hyperuricemia.Modification with polysialic acid-PEG copolymer as a new method for improving the therapeutic efficacy of proteins.
P2860
Q24236711-73680970-4143-4175-B329-15F06369E617Q24616975-6BB02354-F5B6-44E0-89F8-9ED74FEB4B33Q24658504-434B8C5D-80D3-4482-99FC-986821A06C21Q26777819-27BD5D58-80F2-4D76-8B4F-89DB27F5AB37Q26825459-025E88FB-07C4-4D8B-BAFD-59E851189D5DQ27002505-E0798142-409C-4678-81AD-33B42507ABA0Q28552877-198527CC-6588-4F45-AF8E-B55D3B696DF4Q28727969-C28A3FC9-C160-401C-9E91-9C49BF01D252Q28821734-9962EE69-FC47-4F26-9FA8-04E72147FF57Q30234091-FF11395F-3FC2-4E34-9A9F-7D771A093A5DQ30300201-E51753C7-2695-446F-A4E0-8C77E9E576C8Q30393023-913A6EC6-ACDD-464F-B927-EA05E9CAF184Q30398229-4EA2F0CD-CD78-4032-B8C4-3CDAC758C2A0Q32944368-53C08D25-FE75-46D9-9BAC-6DF4ACFD21FFQ33786540-D8E631CE-9CDE-405D-B59E-C430B19F9464Q33902703-D933DC1E-D552-4A8A-9D82-56145EC9C658Q34079574-2EFFB99A-72C5-4841-9D41-53EC46EB11DBQ34542091-91222DF4-E6DC-4898-9C39-774E4D443ABDQ34675491-21C63859-6510-44B6-8603-14D466CA26A2Q35026692-C0DFD02A-C56F-4CE8-8FD9-98EA69EDDC3AQ35843950-FDD46AF2-1026-4A79-A6CC-5DF84A1A4782Q36002499-519EC96F-9DF6-4F9A-9CC1-0C7FB5E9975FQ36515484-3FC74A2B-0AAF-4428-8D64-6A256F4E948EQ36901647-2E709856-3757-49C1-B66F-6626E6E79B40Q37130088-7073DCD7-E633-4575-A619-EC6984D6F2C1Q37350841-D307B5FC-2DF2-42AC-89DA-7B2B813CA124Q37492596-22144599-B791-404A-9351-65FAE19236B8Q37607659-E65B1AF9-C726-45C0-ADC8-5C3CC8C104E7Q37790702-800CFB3D-13E8-4AA6-8EF2-876B716C5ABFQ37815379-C79F8BF5-4E13-47CB-A0AB-192525AD777DQ37950519-1F5E65DE-C066-4D4F-9182-D1137B835FFFQ37971360-3B80E791-A99F-4E34-8B11-BC8A80146079Q37991129-6BE50118-5C87-4973-BEF5-4DDD23F12ECDQ38020590-8079F3E2-605A-4D01-843C-1764109A0C71Q38056075-0E22F59C-9F9E-4CBB-9AF4-DC468871DE2AQ38255726-74597B15-F75B-4182-B39B-EE6935EA953CQ38269324-DBD47D84-351D-4A7E-9C8B-793F78789CD0Q38295898-DE638189-8686-4656-9D07-9542D9887001Q38527441-C7EB7B8D-E9AB-48B5-B6F2-485485D6D53FQ40037958-D486F709-FC91-42AC-99AA-828C4E5B4455
P2860
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@ast
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@en
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@nl
type
label
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@ast
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@en
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@nl
prefLabel
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@ast
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@en
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@nl
P3181
P1476
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
@en
P2093
Mark G P Saifer
Merry R Sherman
P3181
P356
10.1016/J.ADDR.2007.06.011
P407
P577
2008-01-03T00:00:00Z